New recurrent deletions in the PPARγ and TP53 genes are associated with childhood myelodysplastic syndrome

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 19-27

  Silveira, Cássia G T ^a   Oliveira, Fábio M ^b   Valera, Elvis T ^b   Ikoma, Maura R V ^c   Borgonovo, Tamara ^d   Cavalli, Iglenir J ^d   Tone, Luiz G ^b   Rogatto, Silvia R ^a,e  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Amaral Carvalho Hospital   (Brazil)

^d Department of Cell Biology   (Brazil)

^e A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Chromosomal abnormalities; Chromosome 17; Chromosome 3; Deletion; Expression analysis; FISH; GTG banding; Myelodysplasic syndrome; PPAR ; TP53

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P17; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE LOSS; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INFANT; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME BANDING; FEMALE; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KARYOTYPING; MALE; MYELODYSPLASTIC SYNDROMES; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55049115055     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.07.013     Document Type: Article

References (61)

1. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C., and Schimmer A.D. Myelodysplastic syndromes: the complexity of stem cells diseases. Nat Rev Cancer 7 (2007) 118-129
2. Hasle H. Myelodysplastic syndromes in childhood: classification, epidemiology, and treatment. Br J Haematol 13 (1994) 11-26
3. Polychronopoulou S., Panagiotou J.P., Kossiva L., Mavrou A., Anagnostou D., and Haidas S. Clinical and morphological features of paediatric myelodysplastic syndromes: a review of 34 cases. Acta Paediatr 93 (2004) 1015-1023
4. Mitelman F, Johansson B, Mertens F, editors. Mitelman database of chromosome aberrations in cancer, 2007. Available from: http://cgap.nci.nih.gov/Chromosomes/Mitelman.
5. Smith F.O., and Woods W.G. Myeloproliferative and myelodysplastic disorders. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and practice of pediatric oncology (2002), Lippincott Willians and Wilkins, Philadelphia 615-636
6. Chen L.C., Matsumura K., Deng G., Kurisu W., Ljung B.M., Lerman M.I., et al. Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res 54 (1994) 3021-3024
7. Gonzalez M.V., Pello M.F., Ablanedo P., Suarez C., Alvarez V., and Coto E. Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck. J Clin Pathol 51 (1998) 520-524
8. Hirano A., Emi M., Tsuneizumi M., Utada Y., Yoshimoto M., Kasumi F., et al. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 7 (2001) 876-882
9. Johansson B., Billstrom R., Kristoffersson U., Akerman M., Garwicz S., Ahlgren T., et al. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 11 (1997) 1207-1213
10. Kawa S., Nikaido T., Unno H., et al. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 24 (2002) 1-7
11. Bonofiglio D., Aquila S., Catalano S., Gabriele S., Belmonte M., Middea E., et al. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol Endocrinol 20 (2006) 3083-3092
12. Yin F., Wakino S., Liu Z., Kim S., Hsueh W.A., Collins A.R., et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 286 (2001) 916-922
13. Shao J., Sheng H., and DuBois R.N. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 62 (2002) 3282-3288
14. Toyota M., Miyazaki Y., Kitamura S., Nagasawa Y., Kiyohara T., Shinomura Y., et al. Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci 70 (2002) 1565-1575
15. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2 (2002) 594-604
16. Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol 33 (2003) 153-160
17. Watanabe A., Inokuchi K., Yamaguchi H., Mizuki T., Tanosaki S., Shimada T., et al. Near-triploidy and near-tetraploidy in hematological malignancies and mutation of the p53 gene. Clin Lab Haematol 26 (2004) 25-30
18. Lopes L.F., Lorand-Metze I., Niero-Melo L., Tone L.G., Velloso E., Campanaro C.M., et al. The Brazilian Pediatric Myelodysplastic Cooperative Group strategies: are they relevant to improve educational approach and correct diagnosis?. Leuk Res 26 (2002) 637-642
19. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 (1976) 451-458
20. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
21. Scheres V.M.J.C. Identification of two robertsonian translocations with a giemsa banding technique. Hum Genet 15 (1972) 253-256
22. In: Mitelman F. (Ed). ISCN: An international system for human cytogenetic nomenclature (2005), Karger, Basel
23. Rogatto S.R., Rainho C.A., Zhang Z.M., Figueiredo F., Barbieri-Neto J., Georgetto S.M., et al. Hemangioendothelioma of bone in a patient with a constitutional supernumerary marker. Cancer Genet Cytogenet 110 (1999) 23-27
24. Moorhead P.S., Nowell P.C., Mellman W.J., Battips D.M., and Hungerford D.A. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 20 (1960) 613-616
25. Livak K.J., and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
26. Steensma D.P., and List A.F. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 80 (2005) 681-698
27. Panani A.D., and Roussos C. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications. Cancer Lett 235 (2006) 177-190
28. De Souza Fernandez T., Ornellas M.H., Otero de Carvalho L., Tabak D., and Abdelhay E. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res 24 (2000) 839-848
29. Orazi A., Cattoretti G., Heerema N.A., Sozzi G., John K., and Neiman R.S. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies. Modern Pathol 6 (1993) 521-525
30. Brezinova J., Zemanova Z., Ransdorfova S., Sindelarova L., Siskova M., Neuwirtova R., et al. Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160 (2005) 188-192
31. Pinto G.R., Overall D.J., Moraes L.S., Van Den Berg A.V., Lemos J.A.R., Smith M.A.C., et al. Cytogenetic characteristics of patients with signs and symptoms of myelosdysplastic syndromes in the State of Pará. Brazil Genet Mol Res 4 (2005) 18-30
32. Geradts J., Fong K.M., Zimmerman P.V., Maynard R., and Minna J.D. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5 (1999) 791-800
33. Ejeskar K., Aburatani H., Abrahamsson J., Kogner P., and Martinsson T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer 77 (1998) 1787-1791
34. Cigudosa J.C., Parsa N.Z., Louie D.C., Filippa D.A., Jhanwar S.C., Johansson B., et al. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chomosomes Cancer 25 (1999) 123-133
35. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289 (2000) 1357-1360
36. Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B., Aaltonen L.A., et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3 (1999) 799-804
37. Girnun G.D., Smith W.M., Drori S., Sarraf P., Mueller E., Eng C., et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci 99 (2002) 13771-13776
38. Hirase N., Yanase T., Mu Y., Muta K., Umemura T., Takayanagi R., et al. Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562. Leuk Res 24 (2000) 393-400
39. Yamakawa-Karakida N., Sugita K., Inukai T., Goi K., Nakamura M., Uno K., et al. Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ 9 (2002) 513-526
40. Denzlinger C., Dittman K., Mohle A., et al. Peroxisome proliferator activated receptor γ (PPAR-γ) agonists as antileukemic agents in CMML. Blood 98 (2001) 625a
41. Terashita Y., Sasaki H., Haruki N., Nishiwaki T., Ishiguro H., Shibata Y., et al. Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol 32 (2002) 238-243
42. Sasaki H., Tanahashi M., Yukiue H., Moiriyama S., Kobayashi Y., Nakashima Y., et al. Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 36 (2002) 71-76
43. Aldred M.A., Morrison C., Gimm O., Hoang-Vu C., Krause U., Dralle H., et al. Peroxisome proliferator-activated receptor γ is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 22 (2003) 3412-3416
44. Yuan J., Takahashi A., Masumori N., Itoh N., and Tsukamoto T. Peroxisome proliferator activated receptor gamma is frequently underexpressed in renal cell carcinoma. Int J Urol 13 (2006) 265-270
45. Ben-Yehuda D., Krichevsky S., Caspi O., Rund D., Polliack A., Abeliovich D., et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88 (1996) 4296-4303
46. Barouk-Simonet E., Soenen-Cornu V., Roumier C., Cosson A., Lai J.L., Fenaux P., et al. Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases. Cancer Genet Cytogenet 157 (2005) 118-126
47. Jekic B., Novakovic I., Lukovic L., Kuzmanovic M., Popovic B., Milasin J., et al. Lack of TP53 and FMS gene mutations in children with myelodysplastic syndrome. Cancer Genet Cytogenet 166 (2006) 163-165
48. Fujita T., and Kiyama M. Identification of DNA polymorphism by asymmetric PCR-SSCP. Biotechniques 19 (1995) 532
49. Mauritzson N., Johansson B., Albin M., Billstrom R., Ahlgren T., Mikoczy Z., et al. A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender. Eur J Haematol 62 (1999) 95-102
50. Sole F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luno E., et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108 (2000) 346-356
51. Romeo M., Chauffaille M.d.L., Silva M.R., Bahia D.M., and Kerbauy J. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk Res 26 (2002) 993-996
52. Bernasconi P., Cavigliano P.M., Boni M., Calatroni S., Klersy C., Giardini I., et al. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 17 (2003) 2107-2112
53. Breccia M., Mancini M., Nanni M., D'Elia G.M., Carmosino I., Latagliata R., et al. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. Leuk Res 29 (2005) 33-39
54. Han C., Demetris A.J., Michalopoulos G.K., Zhan Q., Shelhamer J.H., and Wu T. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Hepatology 38 (2003) 167-177
55. Nagamine M., Okumura T., Tanno S., Sawamukai M., Motomura W., Takahashi N., et al. PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci 94 (2003) 338-343
56. Okura T., Nakamura M., Takata Y., Watanabe S., Kitami Y., and Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 407 (2000) 227-235
57. Shali W., Helias C., Fohrer C., Struski S., Gervais C., Falkenrodt A., et al. Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH. Cancer Genet Cytogenet 168 (2006) 133-145
58. Pedersen-Bjergaard J., Christiansen D.H., Desta F., and Andersen M.K. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 20 (2006) 1943-1949
59. Meirhaeghe A., and Amouyel P. Impact of genetic variation of PPAR gamma in humans. Mol Genet Metabol 83 (2004) 93-102
60. Petitjean A., Achatz M.I.W., Borresen-Dale A.L., Hainaut1 P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
61. Payne S.R., and Kemp C.J. Tumor suppressor genetics. Carcinogenesis 26 (2005) 2031-2045